FDA probes accuracy with White House rapid virus test

Federal health officials are alerting doctors to a potential accuracy problem with a rapid test for Covid-19 used at thousands of hospitals, clinics and testing sites across the US, including the White House.

The Food and Drug Administration said it was investigating preliminary data suggesting Abbott Laboratories’ 15-minute test can miss Covid-19 cases, falsely clearing patients of infection. The test is used daily at the White House to test President Donald Trump and key members of his staff, including the coronavirus task force.

The warning came one day after researchers at New York University reported results suggesting Abbott’s test can miss up to half the infections caught by a rival test made by Cepheid. The research has not been peer-reviewed or published in a medical journal and was based on about 100 patients.

The researchers found that Abbott’s test, run on the company’s portable ID NOW system, missed one-third of the infections caught by Cepheid’s test when swabs were stored in liquid used to transport laboratory samples. When the samples were kept dry the test missed 48 per cent of the cases flagged by Cepheid’s test.

The researchers called the test’s performance ‘‘unacceptable,’’ due to the risk of falsely clearing patients who could spread the infection to others. They acknowledged shortcomings of the study, including the time needed to transport patient samples to the device for processing.

Abbott rejected the findings, saying the researchers used the test ‘‘in ways that it was not designed to be used.’’

‘‘ID NOW is intended to be used near the patient with a direct swab test method,’’ the company said in a statement. The company pointed to other independent study results that found the test accurately detected 90 per cent or more infections.

Last month Abbott changed the instructions for its test to explicitly warn against putting patient samples in transport chemicals. The update came after researchers at the Cleveland Clinic reported a 15 per cent false negative rate for samples stored in the chemicals.

The FDA said in a statement it was reviewing the data with Abbott and working on a letter to health care providers about potential accuracy issues.

The agency said physicians may need to confirm the results of a negative Abbott test if patients have signs and symptoms of the virus. Regulators said they are requiring Abbott to conduct follow-up studies on the test’s accuracy.

‘‘This test can still be used and can correctly identify many positive cases in minutes,’’ said Dr Tim Stenzel, FDA’s diagnostics director.

The FDA first cleared Abbott’s test in late March under emergency powers used to quickly accelerate the review of tests and treatments during a public health crisis. The agency has authorised more than 90 tests, effectively flooding the market with testing options amid persistent problems ramping up testing levels.

For weeks, Trump has promoted Abbott’s test as a ‘‘game changer.’’

The administration has shipped more than 235,000 of the tests to state public health laboratories.

And Abbott has separately said it has distributed 1.8 million tests to health care facilities in all 50 states.

A White House spokesperson did not immediately respond to a request for comment yesterday.